Back to discover

Protein / target

RNA-directed RNA polymerase

NS5bO39930Hepacivirus hominis
30
Clinical trials
2
Drugs targeting

Protein at a glance

Biological role

RNA-directed RNA polymerase

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Domains and Gene Ontology detail (9)

Domains & features

RdRp catalytic

Gene Ontology

  • FATP binding
  • FATP hydrolysis activity
  • FRNA binding
  • FRNA helicase activity
  • FRNA-directed RNA polymerase activity
  • Fserine-type peptidase activity
  • Pproteolysis
  • Pviral RNA genome replication

591 aa · 66 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

ProteolysisGO
View supporting evidence

Proteolysis

  • ·serine-type peptidase activity
  • ·proteolysis

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 4 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Fibrosis1 medicine
Hepatitis C, Chronic1 medicine
Liver Cirrhosis1 medicine
Virus Diseases1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

2

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Ribavirin
Narrow target profileInhibitor

RNA-directed RNA polymerase inhibitor

Indicated for Fibrosis, Hepatitis C, Chronic, Liver Cirrhosis, Virus Diseases

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ABT-072
Narrow target profileInhibitor

RNA-directed RNA polymerase inhibitor

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

COMPLETED · via Ribavirin · NCT00192569

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Withdrawn from market2023-10-18

    Market withdrawal: Rebetol (EMA)

    ema · market · ema · via Ribavirin

  2. New publication2018-03-14
    Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.

    Journal of viral hepatitis · 2018 · 21 citations · Europe PMC · via Ribavirin

  3. New publication2017-08-10
    Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

    The lancet. Gastroenterology & hepatology · 2017 · 12 citations · Europe PMC · via Ribavirin

  4. New publication2016-10-05
    Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.

    Gastroenterology · 2017 · 126 citations · Europe PMC · via Ribavirin

  5. New publication2016-06-12
    Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.

    Journal of viral hepatitis · 2016 · 10 citations · Europe PMC · via Ribavirin

  6. New publication2015-11-16
    Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

    The New England journal of medicine · 2015 · 586 citations · Europe PMC · via Ribavirin

  7. New publication2015-08-07
    Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.

    Gastroenterology · 2015 · 128 citations · Europe PMC · via Ribavirin

  8. New publication2014-05-09
    ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

    Gastroenterology · 2014 · 266 citations · Europe PMC · via Ribavirin

  9. New publication2014-05-04
    Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

    The New England journal of medicine · 2014 · 578 citations · Europe PMC · via Ribavirin

  10. New publication2014-04-29
    Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.

    Hepatology (Baltimore, Md.) · 2014 · 32 citations · Europe PMC · via Ribavirin

  11. New publication2014-04-10
    Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

    The New England journal of medicine · 2014 · 399 citations · Europe PMC · via Ribavirin

  12. New publication2014-04-10
    Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

    The New England journal of medicine · 2014 · 604 citations · Europe PMC · via Ribavirin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.